- Home
- PEPG
PEPG
PepGen Inc.
as 07-26-2024 4:00pm EST
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 538.8M | IPO Year: | 2022 |
| Target Price: | $23.00 | AVG Volume (30 days): | 153.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.72 - $18.90 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of PepGen Inc. (PEPG)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mellion Michelle L | PEPG | Chief Medical Officer | Jul 18 '24 | Sell | $18.20 | 12,625 | $229,804.04 | 0 | SEC Form 4 |
| Mellion Michelle L | PEPG | Chief Medical Officer | Jul 1 '24 | Sell | $18.07 | 37 | $668.59 | 0 | SEC Form 4 |
| Mellion Michelle L | PEPG | Chief Medical Officer | Jul 1 '24 | Sell | $18.01 | 875 | $15,759.63 | 0 | SEC Form 4 |
| Mellion Michelle L | PEPG | Chief Medical Officer | Jun 24 '24 | Sell | $18.19 | 9,260 | $168,427.36 | 0 | SEC Form 4 |
| Mellion Michelle L | PEPG | Chief Medical Officer | Jun 11 '24 | Sell | $18.04 | 500 | $9,022.00 | 0 | SEC Form 4 |
| Mellion Michelle L | PEPG | Chief Medical Officer | Jun 11 '24 | Sell | $18.06 | 1,086 | $19,614.68 | 0 | SEC Form 4 |
| Mellion Michelle L | PEPG | SVP, Clinical Development | Jun 5 '24 | Sell | $18.09 | 7,245 | $131,062.05 | 0 | SEC Form 4 |
| Mellion Michelle L | PEPG | SVP, Clinical Development | Jun 5 '24 | Sell | $18.00 | 1,411 | $25,398.00 | 0 | SEC Form 4 |
| Svenstrup Niels | PEPG | SVP, Chem. Mfg & Controls | May 17 '24 | Sell | $13.41 | 10,000 | $134,100.00 | 0 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | PEPG | Director10% Owner | Feb 9 '24 | Buy | $10.64 | 2,557,593 | $27,212,789.52 | 9,179,273 | SEC Form 4 |
| McArthur James G | PEPG | President and CEO | Nov 30 '23 | Buy | $4.17 | 1,694 | $7,055.51 | 1,694 | SEC Form 4 |
| Oxford Science Enterprises plc | PEPG | 10% Owner | May 10 '22 | Buy | $12.00 | 879,970 | $10,559,640.00 | 4,755,388 | SEC Form 4 |
Latest PepGen Inc. News
PEPG Breaking Stock News: Dive into PEPG Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why
Business Wire
24 days ago
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
MT Newswires
a month ago
PepGen Names Michelle Mellion as Chief Medical Officer
Business Wire
2 months ago
PepGen Announces Executive Team Promotions
Simply Wall St.
2 months ago
We're Not Very Worried About PepGen's (NASDAQ:PEPG) Cash Burn Rate
MT Newswires
2 months ago
PepGen Q1 Loss Narrows
GlobeNewswire
2 months ago
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Zacks
3 months ago
Best Momentum Stocks to Buy for April 25th
Compare PEPG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PEPG PepGen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.